• Safety & Recalls
  • Regulatory Updates
  • Drug Coverage
  • COPD
  • Cardiovascular
  • Obstetrics-Gynecology & Women's Health
  • Ophthalmology
  • Clinical Pharmacology
  • Pediatrics
  • Urology
  • Pharmacy
  • Idiopathic Pulmonary Fibrosis
  • Diabetes and Endocrinology
  • Allergy, Immunology, and ENT
  • Musculoskeletal/Rheumatology
  • Respiratory
  • Psychiatry and Behavioral Health
  • Dermatology
  • Oncology

AllianceRx Walgreens Prime Home Delivery Earns Reaccreditation

Article

The accreditation is effective through July 2024.

AllianceRx Walgreens Prime has received reaccreditation from URAC for its mail service pharmacy services. URAC is an independent organization focused on promoting healthcare quality through leadership, accreditation, measurement, and innovation. The reaccreditation is effective from July 1, 2021, to July 1, 2024.

Formed in 2017 through a collaboration between Walgreens and Prime Therapeutics, AllianceRx Walgreens Prime is a specialty pharmacy that manages prescriptions for complex, chronic, and rare diseases and conditions. The company is headquartered in Orlando, Fla.

As a specialty pharmacy, AllianceRx Walgreens Prime also helps to connect patients with financial assistance. Over the last two years, the company has connected eligible patients to more than $600 million in financial assistance. The Patient Financial Services team works with patients to identify financial concerns and match them with the appropriate available resources. Resources will vary based on prescribed therapy, diagnosis and prescription drug coverage.

“At AllianceRx Walgreens Prime, we are able to connect eligible patients with such financial resources as co-pay assistance, manufacturer voucher and bridge programs, government subsidies, community and state resources, assistance from disease-specific foundations, and SDOH (social determinants of health) programs,” Lisa Mymo, vice president, Pharma and Financial Services, said in an email. “Through our collaboration with TailorMed, we also have real-time access to information regarding the status of over 5,000 available programs. Improving access to these vital, yet expensive therapies, means our patients are more likely to adhere to treatment and better manage their rare disease or chronic conditions.”

© 2024 MJH Life Sciences

All rights reserved.